Research
Hormonal
Bariatric surgery and pharmacotherapy (e.g., GLP-1 agonists) are indicated for many patients with obesity to achieve and maintain weight loss, especially when lifestyle interventions fail.
If lifestyle changes aren't enough, talk to your doctor about medication or surgery. These treatments target the biology of obesity and can significantly improve health conditions like diabetes and heart disease.
StrongSupportsHIGH confidence
Additional interventions, such as pharmacotherapy or bariatric surgery, are indicated for many patients and should be recommended. Treatment considerations should include assessment of comorbidities or risk factors, as many anti-obesity agents and bariatric surgeries also have beneficial effects on other weight-associated comorbidities.
Why this rating
Guidelines from AHA/ACC/TOS, Endocrine Society, and AACE support these interventions.
Source
Understanding the pathophysiologic pathways that underlie obesity and options for treatment
Rekha B. Kumar et al. · Expert Review of Endocrinology & Metabolism · 2021
DOI 10.1080/17446651.2021.1991310
narrative_reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is a chronic disease driven by pathophysiologic dysregulation of energy balance (neural, hormonal, metabolic pathways), not merely a behavioral failure of discipline.Strong
- Lifestyle interventions (diet/exercise) are the cornerstone of obesity treatment but are rarely sufficient for long-term weight maintenance due to metabolic adaptations.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →